BillionToOne, Inc. BLLN
BillionToOne, Inc. (Nasdaq: BLLN) is a diagnostics company. Its next catalyst on record is pan-cancer MRD test: commercial availability (December 2026).
Upcoming catalysts
- December 2026pan-cancer MRD test — commercial availability
We are developing a tissue-free, pan-cancer MRD test, which we expect to be commercially available in December of 2026.
Next further out: Austin, Texas laboratory facility — facility occupation (2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| pan-cancer MRD test | minimal residual disease detection post-surgery | unclear | Pre-clinical |
| UNITY Fetal Risk Screen | prenatal genetic screening - comprehensive | unclear | NA_NON_THERAPEUTIC |
| Unity Confirm | non-invasive confirmation of high-risk prenatal screening results | unclear | NA_NON_THERAPEUTIC |
| Northstar Select | pan-cancer therapy selection | unclear | NA_NON_THERAPEUTIC |
| Northstar Response | pan-cancer treatment monitoring (methylation-based tumor burden) | unclear | NA_NON_THERAPEUTIC |
| Northstar PGx | chemotherapy safety pharmacogenomics | unclear | NA_NON_THERAPEUTIC |
| Northstar Select CH | clonal hematopoiesis profiling | unclear | NA_NON_THERAPEUTIC |
| Northstar Origin | tissue-of-origin identification | unclear | NA_NON_THERAPEUTIC |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.